menu
    • menu
    [{"orgOrder":0,"company":"Neuraxpharm","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Ublituximab","moa":"B-lymphocyte antigen CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neuraxpharm","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.65000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuraxpharm \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Neuraxpharm \/ Neuraxpharm"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"TG Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Ublituximab","moa":"B-lymphocyte antigen CD20","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neuraxpharm","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.65000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Neuraxpharm \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Neuraxpharm \/ Neuraxpharm"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Controlled Substance","year":"2020","type":"Acquisition","leadProduct":"Diazepam","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Neuraxpharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Neuraxpharm \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Neuraxpharm \/ Neuraxpharm"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Acquisition","leadProduct":"Modafinil","moa":"Dopamine transporter","graph1":"Sleep","graph2":"Approved FDF","graph3":"Neuraxpharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neuraxpharm \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Neuraxpharm \/ Neuraxpharm"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Lamotrigine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neuraxpharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neuraxpharm \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Neuraxpharm \/ Neuraxpharm"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Levomepromazine Maleate","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Neuraxpharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neuraxpharm \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Neuraxpharm \/ Neuraxpharm"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Levomepromazine Maleate","moa":"DRD2","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Neuraxpharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neuraxpharm \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Neuraxpharm \/ Neuraxpharm"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Panaxia","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"Neuraxpharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Neuraxpharm \/ Neuraxpharm","highestDevelopmentStatusID":"1","companyTruncated":"Neuraxpharm \/ Neuraxpharm"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Brain Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"GREECE","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Midazolam Maleate","moa":"GABR","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neuraxpharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Inhalation","sponsorNew":"Neuraxpharm \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Neuraxpharm \/ Neuraxpharm"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"JAPAN","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Midazolam Maleate","moa":"GABR","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neuraxpharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Inhalation","sponsorNew":"Neuraxpharm \/ Neuraxpharm","highestDevelopmentStatusID":"15","companyTruncated":"Neuraxpharm \/ Neuraxpharm"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Midazolam Maleate","moa":"GABR","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neuraxpharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oromucosal Inhalation","sponsorNew":"Neuraxpharm \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"Neuraxpharm \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Permira","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Acquisition","leadProduct":"Midazolam Maleate","moa":"GABR","graph1":"Neurology","graph2":"Approved FDF","graph3":"Neuraxpharm","amount2":1.8799999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":1.8799999999999999,"dosageForm":"Pre-Filled Injection","sponsorNew":"Neuraxpharm \/ Permira","highestDevelopmentStatusID":"15","companyTruncated":"Neuraxpharm \/ Permira"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Pharmathen SA","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GREECE","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Neuraxpharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neuraxpharm \/ Neuraxpharm","highestDevelopmentStatusID":"1","companyTruncated":"Neuraxpharm \/ Neuraxpharm"},{"orgOrder":0,"company":"Neuraxpharm","sponsor":"Panaxia","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Neuraxpharm","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuraxpharm \/ Panaxia","highestDevelopmentStatusID":"1","companyTruncated":"Neuraxpharm \/ Panaxia"}]

    Find Clinical Drug Pipeline Developments & Deals by Neuraxpharm

    Menu

    Neuraxpharm

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Neuraxpharm

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Neuraxpharm

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Modafinil

                            Therapeutic Area : Sleep

                            Study Phase : Approved FDF

                            Recipient : Teva Pharmaceutical Industries

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Neuraxpharm Acquires Provigil®, Nuvigil® to Expand Branded Business

                            Details : Neuraxpharm has acquired these products Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of EDS in adults with narcolepsy.

                            Product Name : Provigil

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 07, 2025

                            Lead Product(s) : Modafinil

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved FDF

                            Recipient : Teva Pharmaceutical Industries

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Neuraxpharm

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Neuraxpharm

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Undisclosed

                            Recipient : Pharmathen SA

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Neuraxpharm and Pharmathen Enter into Agreement to Develop Long-acting Therapies

                            Details : The agreement aims to co-develop new long-acting injectable therapies within the psychiatry field under Pharmathen’s long-acting therapeutic technologies (LATT) program.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            December 12, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Undisclosed

                            Recipient : Pharmathen SA

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Neuraxpharm

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Neuraxpharm

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ublituximab

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : TG Therapeutics

                            Deal Size : $645.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)

                            Details : Through agreement, Neuraxpharm will focus on the commercialization of Briumvi (ublituximab) in Europe, for the treatment of adults patients with relapsing forms of multiple sclerosis.

                            Product Name : Briumvi

                            Product Type : Antibody

                            Upfront Cash : $152.5 million

                            February 26, 2024

                            Lead Product(s) : Ublituximab

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : TG Therapeutics

                            Deal Size : $645.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Neuraxpharm

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Neuraxpharm

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ublituximab

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : TG Therapeutics

                            Deal Size : $645.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy)

                            Details : Under the agreement, TG Therapeutics will commercialise Briumvi (ublituximab), the first and only anti-CD20 monoclonal antibody approved in the United States and European Union for adult patients with relapsing forms of multiple sclerosis.

                            Product Name : Briumvi

                            Product Type : Antibody

                            Upfront Cash : $140.0 million

                            January 08, 2023

                            Lead Product(s) : Ublituximab

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : TG Therapeutics

                            Deal Size : $645.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Neuraxpharm

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Neuraxpharm

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levomepromazine Maleate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Recipient : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Neuraxpharm Announces Closing of Acquisition of Established Products from Sanofi

                            Details : The acquisition will strengthen Neuraxpharm's position as a leading company focused on CNS by including 2 product portfolios for CNS disorders, pain and vascular diseases. The CNS portfolio includes Nozinan (levomepromazine maleate), Tranxene, Tiapridal,...

                            Product Name : Nozinan

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            January 02, 2023

                            Lead Product(s) : Levomepromazine Maleate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Recipient : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Neuraxpharm

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Neuraxpharm

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Levomepromazine Maleate

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Recipient : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Neuraxpharm to Increase Branded Business Through Upcoming Acquisition of Established Products from Sanofi

                            Details : Nozinan (levomepromazine) is a neuroleptic with indications in psychiatry and general medicine, particularly in terminal illness. Clinically it is more sedative and more potent than chlorpromazine in management of psychotic conditions and in relief of se...

                            Product Name : Nozinan

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 07, 2022

                            Lead Product(s) : Levomepromazine Maleate

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Recipient : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Neuraxpharm

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Neuraxpharm

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Midazolam Maleate

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Brain Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Neuraxpharm Expands Its Business in Southeast Europe

                            Details : Having acquired Brain Therapeutics, Neuraxpharm is now able to bring new products to the Greek market including the market-leading product for emergency treatment of children and adolescents with epilepsy, Buccolam®, will be among the products to be off...

                            Product Name : Buccolam

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 03, 2022

                            Lead Product(s) : Midazolam Maleate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Brain Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Neuraxpharm

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Neuraxpharm

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Midazolam Maleate

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Neuraxpharm Launches First Product in Japan

                            Details : Buccolam (oromucosal midazolam), value-added buccal midazolam indicated for emergency treatment of children and adolescents from 3 months to 18 years with epilepsy suffering from prolonged acute convulsive seizures.

                            Product Name : Buccolam

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 01, 2021

                            Lead Product(s) : Midazolam Maleate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Neuraxpharm

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Neuraxpharm

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Midazolam Maleate

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Permira

                            Deal Size : $1,880.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Permira Funds to Acquire Leading European CNS Specialty Pharmaceutical Company Neuraxpharm

                            Details : The Permira funds will support the management’s vision of becoming the leading CNS-focused specialty pharmaceutical platform in Europe through driving the commercialization of Neuraxpharm’s attractive new product pipeline and support further its expa...

                            Product Name : Buccolam

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 22, 2020

                            Lead Product(s) : Midazolam Maleate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Permira

                            Deal Size : $1,880.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Neuraxpharm

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed

                            Neuraxpharm

                            Spain arrow
                            CPHI Shenzhen
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Midazolam Maleate

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Recipient : Takeda Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Neuraxpharm Acquires Market-Leading Buccolam® For Emergency Treatment of Epileptic Children

                            Details : Buccolam® (Midazolam), fits perfectly within Neuraxpharm’s portfolio, strengthening its position as the European CNS specialist in several European countries, and offers the opportunity to expand the commercial footprint, including into the Nordics an...

                            Product Name : Buccolam

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            September 14, 2020

                            Lead Product(s) : Midazolam Maleate

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Recipient : Takeda Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth